Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 7 of 7 entries
Sorted by: Best Match Show Resources per page
[No title available]

JMM case reports

Treguier P, David M, Gargala G, Camus V, Stamatoullas A, Menard AL, Lenain P, Contentin N, Lemasle E, Lanic H, Tilly H, Jardin F, Lepretre S.
PMID: 30323936
JMM Case Rep. 2018 Jul 10;5(8):e005160. doi: 10.1099/jmmcr.0.005160. eCollection 2018 Aug.

No abstract available.

Cite
Treguier P, David M, Gargala G, et al. . JMM Case Rep. 2018;5(8):e005160doi: 10.1099/jmmcr.0.005160.
Treguier, P., David, M., Gargala, G., Camus, V., Stamatoullas, A., Menard, A. L., Lenain, P., Contentin, N., Lemasle, E., Lanic, H., Tilly, H., Jardin, F., & Lepretre, S. (2018). . JMM case reports, 5(8), e005160. https://doi.org/10.1099/jmmcr.0.005160
Treguier, Pauline, et al. "." JMM case reports vol. 5,8 (2018): e005160. doi: https://doi.org/10.1099/jmmcr.0.005160
Treguier P, David M, Gargala G, Camus V, Stamatoullas A, Menard AL, Lenain P, Contentin N, Lemasle E, Lanic H, Tilly H, Jardin F, Lepretre S. . JMM Case Rep. 2018 Jul 10;5(8):e005160. doi: 10.1099/jmmcr.0.005160. eCollection 2018 Aug. PMID: 30323936; PMCID: PMC6152400.
Copy Download .nbib Format: NLM
Dissociated humoral and cellular immune responses after a three-dose schema of BNT162b2 vaccine in patients receiving anti-CD20 monoclonal antibody maintenance treatment for B-cell lymphomas.

Haematologica

Candon S, Lemee V, Leveque E, Etancelin P, Paquin C, Carette M, Contentin N, Bobee V, Alani M, Cardinael N, Lepretre S, Camus V, Bouclet F, Boulet E, Menard AL, Lanic H, Stamatoullas A, Lemasle E, Pepin LF, Richard D, Dubois S, Tilly H, Dalleac A, Plantier JC, Etienne M, Jardin F.
PMID: 34854280
Haematologica. 2021 Dec 02; doi: 10.3324/haematol.2021.280139. Epub 2021 Dec 02.

Not available.

Cite
Candon S, Lemee V, Leveque E, et al. Dissociated humoral and cellular immune responses after a three-dose schema of BNT162b2 vaccine in patients receiving anti-CD20 monoclonal antibody maintenance treatment for B-cell lymphomas. Haematologica. 2021;doi: 10.3324/haematol.2021.280139.
Candon, S., Lemee, V., Leveque, E., Etancelin, P., Paquin, C., Carette, M., Contentin, N., Bobee, V., Alani, M., Cardinael, N., Lepretre, S., Camus, V., Bouclet, F., Boulet, E., Menard, A. L., Lanic, H., Stamatoullas, A., Lemasle, E., Pepin, L. F., Richard, D., Dubois, S., Tilly, H., Dalleac, A., Plantier, J. C., Etienne, M., & Jardin, F. (2021). Dissociated humoral and cellular immune responses after a three-dose schema of BNT162b2 vaccine in patients receiving anti-CD20 monoclonal antibody maintenance treatment for B-cell lymphomas. Haematologica, . https://doi.org/10.3324/haematol.2021.280139
Candon, Sophie, et al. "Dissociated humoral and cellular immune responses after a three-dose schema of BNT162b2 vaccine in patients receiving anti-CD20 monoclonal antibody maintenance treatment for B-cell lymphomas." Haematologica vol. (2021). doi: https://doi.org/10.3324/haematol.2021.280139
Candon S, Lemee V, Leveque E, Etancelin P, Paquin C, Carette M, Contentin N, Bobee V, Alani M, Cardinael N, Lepretre S, Camus V, Bouclet F, Boulet E, Menard AL, Lanic H, Stamatoullas A, Lemasle E, Pepin LF, Richard D, Dubois S, Tilly H, Dalleac A, Plantier JC, Etienne M, Jardin F. Dissociated humoral and cellular immune responses after a three-dose schema of BNT162b2 vaccine in patients receiving anti-CD20 monoclonal antibody maintenance treatment for B-cell lymphomas. Haematologica. 2021 Dec 02; doi: 10.3324/haematol.2021.280139. Epub 2021 Dec 02. PMID: 34854280.
Copy Download .nbib Format: NLM
Multiple cutaneous ulcers revealing a primary cutaneous Epstein-Barr virus-positive diffuse large B-cell lymphoma.

Clinical case reports

Tedbirt B, Dubois S, Cellier L, Carvalho P, Stamatoullas A, Courville P, Deschamps-Huvier A, Etancelin P, Deniel A, Tilly H, Jardin F, Joly P, Camus V.
PMID: 33363783
Clin Case Rep. 2020 Aug 10;8(12):2578-2582. doi: 10.1002/ccr3.3239. eCollection 2020 Dec.

Primary cutaneous EBV-positive diffuse large B-cell lymphoma is an exceptional and aggressive neoplasia with a poorer prognosis than other cutaneous lymphoma. Our observation points out the rarity of the presentation and the dismal clinical course.

Cite
Tedbirt B, Dubois S, Cellier L, et al. Multiple cutaneous ulcers revealing a primary cutaneous Epstein-Barr virus-positive diffuse large B-cell lymphoma. Clin Case Rep. 2020;8(12):2578-2582doi: 10.1002/ccr3.3239.
Tedbirt, B., Dubois, S., Cellier, L., Carvalho, P., Stamatoullas, A., Courville, P., Deschamps-Huvier, A., Etancelin, P., Deniel, A., Tilly, H., Jardin, F., Joly, P., & Camus, V. (2020). Multiple cutaneous ulcers revealing a primary cutaneous Epstein-Barr virus-positive diffuse large B-cell lymphoma. Clinical case reports, 8(12), 2578-2582. https://doi.org/10.1002/ccr3.3239
Tedbirt, Billal, et al. "Multiple cutaneous ulcers revealing a primary cutaneous Epstein-Barr virus-positive diffuse large B-cell lymphoma." Clinical case reports vol. 8,12 (2020): 2578-2582. doi: https://doi.org/10.1002/ccr3.3239
Tedbirt B, Dubois S, Cellier L, Carvalho P, Stamatoullas A, Courville P, Deschamps-Huvier A, Etancelin P, Deniel A, Tilly H, Jardin F, Joly P, Camus V. Multiple cutaneous ulcers revealing a primary cutaneous Epstein-Barr virus-positive diffuse large B-cell lymphoma. Clin Case Rep. 2020 Aug 10;8(12):2578-2582. doi: 10.1002/ccr3.3239. eCollection 2020 Dec. PMID: 33363783; PMCID: PMC7752427.
Copy Download .nbib Format: NLM
Positron Emission Tomography-Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Casasnovas RO, Bouabdallah R, Brice P, Lazarovici J, Ghesquieres H, Stamatoullas A, Dupuis J, Gac AC, Gastinne T, Joly B, Bouabdallah K, Nicolas-Virelizier E, Feugier P, Morschhauser F, Sibon D, Bonnet C, Berriolo-Riedinger A, Edeline V, Parrens M, Damotte D, Coso D, André M, Meignan M, Rossi C.
PMID: 34990281
J Clin Oncol. 2022 Jan 06;JCO2101777. doi: 10.1200/JCO.21.01777. Epub 2022 Jan 06.

PURPOSE: The AHL2011 study (ClinicalTrials.gov identifier: NCT01358747) demonstrated that a positron emission tomography (PET)-driven de-escalation strategy after two cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP) provides similar progression-free survival (PFS) and overall survival (OS) and...

Cite
Casasnovas RO, Bouabdallah R, Brice P, et al. Positron Emission Tomography-Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study. J Clin Oncol. 2022;JCO2101777doi: 10.1200/JCO.21.01777.
Casasnovas, R. O., Bouabdallah, R., Brice, P., Lazarovici, J., Ghesquieres, H., Stamatoullas, A., Dupuis, J., Gac, A. C., Gastinne, T., Joly, B., Bouabdallah, K., Nicolas-Virelizier, E., Feugier, P., Morschhauser, F., Sibon, D., Bonnet, C., Berriolo-Riedinger, A., Edeline, V., Parrens, M., Damotte, D., Coso, D., André, M., Meignan, M., & Rossi, C. (2022). Positron Emission Tomography-Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, JCO2101777. https://doi.org/10.1200/JCO.21.01777
Casasnovas, René-Olivier, et al. "Positron Emission Tomography-Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study." Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. (2022): JCO2101777. doi: https://doi.org/10.1200/JCO.21.01777
Casasnovas RO, Bouabdallah R, Brice P, Lazarovici J, Ghesquieres H, Stamatoullas A, Dupuis J, Gac AC, Gastinne T, Joly B, Bouabdallah K, Nicolas-Virelizier E, Feugier P, Morschhauser F, Sibon D, Bonnet C, Berriolo-Riedinger A, Edeline V, Parrens M, Damotte D, Coso D, André M, Meignan M, Rossi C. Positron Emission Tomography-Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study. J Clin Oncol. 2022 Jan 06;JCO2101777. doi: 10.1200/JCO.21.01777. Epub 2022 Jan 06. PMID: 34990281.
Copy Download .nbib Format: NLM
Outcomes of refractory or relapsed Hodgkin lymphoma patients with post autologous stem cell transplantation brentuximab vedotin maintenance : a French multicenter observational cohort study.

Haematologica

Marouf A, Cottereau AS, Kanoun S, Deschamps P, Meignan M, Franchi P, Sibon D, Antoine C, Gastinne T, Borel C, Hammoud M, Sicard G, Gille R, Cavalieri D, Stamatoullas A, Filliatre-Clement L, Lazarovici J, Chauchet A, Fornecker LM, Amorin S, Rocquet M, Raus N, Burroni B, Rubio MT, Bouscary D, Quittet P, Casasnovas RO, Brice P, Ghesquieres H, Tamburini J, Deau B.
PMID: 34965701
Haematologica. 2021 Dec 30; doi: 10.3324/haematol.2021.279564. Epub 2021 Dec 30.

Not available.

Cite
Marouf A, Cottereau AS, Kanoun S, et al. Outcomes of refractory or relapsed Hodgkin lymphoma patients with post autologous stem cell transplantation brentuximab vedotin maintenance : a French multicenter observational cohort study. Haematologica. 2021;doi: 10.3324/haematol.2021.279564.
Marouf, A., Cottereau, A. S., Kanoun, S., Deschamps, P., Meignan, M., Franchi, P., Sibon, D., Antoine, C., Gastinne, T., Borel, C., Hammoud, M., Sicard, G., Gille, R., Cavalieri, D., Stamatoullas, A., Filliatre-Clement, L., Lazarovici, J., Chauchet, A., Fornecker, L. M., Amorin, S., Rocquet, M., Raus, N., Burroni, B., Rubio, M. T., Bouscary, D., Quittet, P., Casasnovas, R. O., Brice, P., Ghesquieres, H., Tamburini, J., & Deau, B. (2021). Outcomes of refractory or relapsed Hodgkin lymphoma patients with post autologous stem cell transplantation brentuximab vedotin maintenance : a French multicenter observational cohort study. Haematologica, . https://doi.org/10.3324/haematol.2021.279564
Marouf, Amira, et al. "Outcomes of refractory or relapsed Hodgkin lymphoma patients with post autologous stem cell transplantation brentuximab vedotin maintenance : a French multicenter observational cohort study." Haematologica vol. (2021). doi: https://doi.org/10.3324/haematol.2021.279564
Marouf A, Cottereau AS, Kanoun S, Deschamps P, Meignan M, Franchi P, Sibon D, Antoine C, Gastinne T, Borel C, Hammoud M, Sicard G, Gille R, Cavalieri D, Stamatoullas A, Filliatre-Clement L, Lazarovici J, Chauchet A, Fornecker LM, Amorin S, Rocquet M, Raus N, Burroni B, Rubio MT, Bouscary D, Quittet P, Casasnovas RO, Brice P, Ghesquieres H, Tamburini J, Deau B. Outcomes of refractory or relapsed Hodgkin lymphoma patients with post autologous stem cell transplantation brentuximab vedotin maintenance : a French multicenter observational cohort study. Haematologica. 2021 Dec 30; doi: 10.3324/haematol.2021.279564. Epub 2021 Dec 30. PMID: 34965701.
Copy Download .nbib Format: NLM
Spontaneous remission in three cases of AML M5 with NPM1 mutation.

Clinical case reports

Camus V, Etancelin P, Jardin F, Lenain P, Contentin N, Daliphard S, Buchonnet G, Lemasle E, Lanic H, Leprêtre S, Penther D, Dubois S, Tilly H, Bastard C, Stamatoullas A.
PMID: 26576281
Clin Case Rep. 2015 Nov;3(11):955-9. doi: 10.1002/ccr3.408. Epub 2015 Oct 21.

Patients with NPM1-mutated AML M5 who develop spontaneous remission (SR) after antibiotic therapy at diagnosis seem to form a favorable prognosis and chemo sensitive subtype. We report three cases of AML M5 patients with the same genotype that experienced...

Cite
Camus V, Etancelin P, Jardin F, et al. Spontaneous remission in three cases of AML M5 with NPM1 mutation. Clin Case Rep. 2015;3(11):955-9doi: 10.1002/ccr3.408.
Camus, V., Etancelin, P., Jardin, F., Lenain, P., Contentin, N., Daliphard, S., Buchonnet, G., Lemasle, E., Lanic, H., Leprêtre, S., Penther, D., Dubois, S., Tilly, H., Bastard, C., & Stamatoullas, A. (2015). Spontaneous remission in three cases of AML M5 with NPM1 mutation. Clinical case reports, 3(11), 955-9. https://doi.org/10.1002/ccr3.408
Camus, Vincent, et al. "Spontaneous remission in three cases of AML M5 with NPM1 mutation." Clinical case reports vol. 3,11 (2015): 955-9. doi: https://doi.org/10.1002/ccr3.408
Camus V, Etancelin P, Jardin F, Lenain P, Contentin N, Daliphard S, Buchonnet G, Lemasle E, Lanic H, Leprêtre S, Penther D, Dubois S, Tilly H, Bastard C, Stamatoullas A. Spontaneous remission in three cases of AML M5 with NPM1 mutation. Clin Case Rep. 2015 Nov;3(11):955-9. doi: 10.1002/ccr3.408. Epub 2015 Oct 21. PMID: 26576281; PMCID: PMC4641483.
Copy Download .nbib Format: NLM
Correction to: Risk of relapse after anti-PD1 discontinuation in patients with Hodgkin lymphoma.

European journal of nuclear medicine and molecular imaging

Manson G, Brice P, Herbaux C, Silva MG, Bouabdallah K, Deau B, Bouteloup J, Schiano JM, Nicolas-Virelizier E, Maerevoet M, Ghesquieres H, Stamatoullas A, Antier C, Carlo-Stella C, de Charette M, Poizeau F, Dercle L, Houot R.
PMID: 33745014
Eur J Nucl Med Mol Imaging. 2021 May;48(5):1699-1700. doi: 10.1007/s00259-021-05321-3.

No abstract available.

Cite
Manson G, Brice P, Herbaux C, et al. Correction to: Risk of relapse after anti-PD1 discontinuation in patients with Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2021;48(5):1699-1700doi: 10.1007/s00259-021-05321-3.
Manson, G., Brice, P., Herbaux, C., Silva, M. G., Bouabdallah, K., Deau, B., Bouteloup, J., Schiano, J. M., Nicolas-Virelizier, E., Maerevoet, M., Ghesquieres, H., Stamatoullas, A., Antier, C., Carlo-Stella, C., de Charette, M., Poizeau, F., Dercle, L., & Houot, R. (2021). Correction to: Risk of relapse after anti-PD1 discontinuation in patients with Hodgkin lymphoma. European journal of nuclear medicine and molecular imaging, 48(5), 1699-1700. https://doi.org/10.1007/s00259-021-05321-3
Manson, G, et al. "Correction to: Risk of relapse after anti-PD1 discontinuation in patients with Hodgkin lymphoma." European journal of nuclear medicine and molecular imaging vol. 48,5 (2021): 1699-1700. doi: https://doi.org/10.1007/s00259-021-05321-3
Manson G, Brice P, Herbaux C, Silva MG, Bouabdallah K, Deau B, Bouteloup J, Schiano JM, Nicolas-Virelizier E, Maerevoet M, Ghesquieres H, Stamatoullas A, Antier C, Carlo-Stella C, de Charette M, Poizeau F, Dercle L, Houot R. Correction to: Risk of relapse after anti-PD1 discontinuation in patients with Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2021 May;48(5):1699-1700. doi: 10.1007/s00259-021-05321-3. PMID: 33745014.
Copy Download .nbib Format: NLM
Showing 1 to 7 of 7 entries